Emergent BioSolutions highlights several recent advancements

Emergent BioSolutions highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company’s overall debt. This disciplined approach has enhanced Emergent’s financial position, as well as enabling a customer focused, leaner and more flexible organization, and enriching its opportunities to pursue strategic initiatives. Emergent’s recent actions include: Secured $250 million in U.S. government contract award modifications for four medical countermeasures; Announced a $30 million definitive agreement to sell its Baltimore-Camden manufacturing site; Received $7 million for sale of its unimproved, empty building in Canton, Massachusetts; As disclosed yesterday in its SEC filing, the resolution of its contract dispute with Janssen Pharmaceuticals, including the impending receipt of $50 million in the third quarter of this year; Expected receipt of a development milestone payment as part of its Travel Health Business sale by year end